Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

Bibliographic Details
Main Authors:	KM Erny-Albrecht, E Erdmann
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2009-03-01
Series:	Swiss Medical Weekly
Subjects:	Macrovascular events Costeffectiveness Switzerland PRO active Pioglitazone type 2 diabetes mellitus
Online Access:	https://www.smw.ch/index.php/smw/article/view/956

Similar Items

Economic and clinical impact of alternative disease management strategies for secondary prevention in diabetes type 2 in the Swiss setting
by: V Gozzoli, et al.
Published: (2001-06-01)

Symposium 13: Impact of prediabetes on macrovascular disease
by: Carolina Gómez Martin
Published: (2022-09-01)

Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications
by: Wei Yang, et al.
Published: (2017-10-01)

Associations between Circulating Markers of Cholesterol Homeostasis and Macrovascular Events among Patients Undergoing Hemodialysis
by: Wen-Chin Lee, et al.
Published: (2021-03-01)

Associations of Thyroid Hormone Levels and Macrovascular Complications in Euthyroid Type 2 Diabetic Patients
by: Hu Y, et al.
Published: (2021-06-01)

Clinical characteristics and risk factors of macrovascular diseases in patients with different subtypes of type 1 diabetes mellitus
by: WANG Liting, XU Lingling, LI Wei, PING Fan, ZHANG Huabing, MA Yahong, LI Yuxiu
Published: (2023-08-01)

Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
by: Aastha Chawla, et al.
Published: (2016-01-01)

Echocardiographic quantification of atherosclerosis leads to cost-effective treatment with statins
by: V Barbosa
Published: (2005-01-01)

Subclinical Hypothyroidism as a Contributor to Macrovascular Complications in Patients with Type 2 Diabetes Mellitus
by: Mariya Marushchak, et al.
Published: (2021-01-01)

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
by: M. V. Shestakova, et al.
Published: (2021-07-01)

The importance of self-control, and education of patients with diabetes mellitus type 2 in the prevention of micro and macrovascular complications
by: Sandra Živanović, et al.
Published: (2013-01-01)

Risk management of micro- and macrovascular complications of diabetes mellitus: the importance of glycemic self-control
by: Olga A. Polyakova, et al.
Published: (2021-08-01)

Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
by: Chin-Hsiao Tseng
Published: (2022-05-01)

The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies
by: Pantea Ramezannezhad, et al.
Published: (2023-03-01)

Effect of Pioglitazone and Levo-Carnitine on Plasma Glucose, Insulin Resistance and Serum Adiponectin in Type 2 Diabetic Mice
by: Shahida Parveen
Published: (2014-06-01)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
by: Hae Jin Kim, et al.
Published: (2022-09-01)

Effects of Resveratrol on pharmacokinetics and pharmacodynamics of Pioglitazone in Diabetic rats
by: Raju Devde1 , Narasimha Reddy Y2 , Sravanthi K3 , Abid Ali4 , Imran Khan5
Published: (2017-04-01)

The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance
by: H.M. Al-Muzafar, et al.
Published: (2021-05-01)

Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion
by: Che-Jui Chang, et al.
Published: (2023-11-01)

Pioglitazone - the forgotten drug with multidirectional action
by: Arkadiusz Aab, et al.
Published: (2023-04-01)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
by: Schwartz S
Published: (2010-07-01)

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2022-12-01)

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
by: Mondal Aashish, et al.
Published: (2024-02-01)

Advances in secondary prevention mechanisms of macrovascular complications in type 2 diabetes mellitus patients: a comprehensive review
by: Huifang Guan, et al.
Published: (2024-03-01)

Pioglitazone use and the risk of bladder cancer
by: Hsin-Wei Kuo, et al.
Published: (2014-02-01)

Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent
by: V. V. Salukhov, et al.
Published: (2022-06-01)

The Prediction of Macrovascular Complications in Individuals with Type 2 diabetes mellitus with Different Risk Factors in ThiQar
by: Shahad Turkey Mana, et al.
Published: (2023-04-01)

Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study
by: Eugenio Ragazzi, et al.
Published: (2023-08-01)

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population
by: V Balaji, et al.
Published: (2014-01-01)

The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats
by: Ahmed Mohamed Othman, et al.
Published: (2023-12-01)

Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
by: Jingen Li, et al.
Published: (2024-01-01)

Predominant Complications of Type 2 Diabetes in Kumasi: A 4-Year Retrospective Cross-Sectional Study at a Teaching Hospital in Ghana
by: Max Efui Annani-Akollor, et al.
Published: (2019-05-01)

Editorial: Reducing cardiovascular disease mortality and morbidity: implementing cost-effective and sustainable preventive interventions
by: Shanthi Mendis, et al.
Published: (2023-06-01)

Effect of pioglitazone treatment on serum chemerin and vaspin levels in polycystic ovary syndrome.
by: Rana Hussein Kutaif, et al.
Published: (2022-04-01)

Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice
by: Lea Helena Kunze, et al.
Published: (2023-06-01)

Effect of Pioglitazone on Plasma Levels of Phenytoin in Rats
by: Hamed Ghavimi, et al.
Published: (2013-10-01)

Variant rs2237892 of KCNQ1 Is Potentially Associated with Hypertension and Macrovascular Complications in Type 2 Diabetes Mellitus in A Chinese Han Population
by: Wanlin Zhang, et al.
Published: (2015-12-01)

The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19)
by: Gemma Llauradó, et al.
Published: (2022-10-01)

The risk of micro and macrovascular disease in Egyptian patients with diabetes and peripheral arterial disease
by: Maha Assem, et al.
Published: (2021-03-01)

Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial
by: Rana Arashnia, et al.
Published: (2015-10-01)